Homology Medicines (Homology Medicines) Forward PE Ratio : 0.00 (As of Apr. 30, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines Forward PE Ratio?

Homology Medicines's Forward PE Ratio for today is 0.00.

Homology Medicines's PE Ratio without NRI for today is 0.00.

Homology Medicines's PE Ratio for today is 0.00.

Homology Medicines Forward PE Ratio Historical Data

The historical data trend for Homology Medicines's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines Forward PE Ratio Chart

Homology Medicines Annual Data

Trend

2022-08

Forward PE Ratio

27.03

Homology Medicines Quarterly Data

Forward PE Ratio

Competitive Comparison of Homology Medicines's Forward PE Ratio

For the Biotechnology subindustry, Homology Medicines's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Homology Medicines's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Homology Medicines's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Homology Medicines's Forward PE Ratio falls into.

Homology Medicines Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Homology Medicines (NAS:FIXX) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Homology Medicines Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Homology Medicines's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Homology Medicines (Homology Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (NAS:FIXX) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

35H:Germany

Address

One Patriots Park, Bedford, MA, USA, 01730

Website

https://www.homologymedicines.com

Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Executives

Paul Alloway	officer: See Remarks	C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Albert Seymour	officer: Chief Scientific Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Julie Jordan	officer: Chief Medical Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Michael Lee Blum	officer: Chief Commercial Officer	C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
W Bradford Smith	officer: CFO, Treasurer & Secretary	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Arthur Tzianabos	director, officer: President & CEO	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Timothy P Kelly	officer: See Remarks	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Gabriel Cohn	officer: Chief Medical Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Iv, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jeffrey V. Poulton	director	300 THIRD STREET, CAMBRIDGE MA 02142
James E Flynn	director, 10 percent owner, other: *Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Alise Reicin	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Siyamak Rasty	officer: Chief Operating Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Vida Ventures, Llc	10 percent owner	40 BROAD STREET, SUITE 201, BOSTON MA 02109